Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity
The diagnostic of SARS-CoV-2 infection relies on reverse transcriptase polymerase chain reactions (RT-PCRs) performed on nasopharyngeal (NP) swabs. Nevertheless, false-negative results can be obtained with inadequate sampling procedures, making the use of other biological matrices worthy of investigation. This study aims to evaluate the kinetics of serum N antigens in severe and non-severe patients and compare the clinical performance of serum antigenic assays with NP RT-PCR. Ninety patients were included in the study and monitored for several days. Disease severity was determined according to the WHO clinical progression scale. Serum N antigen levels were measured with a chemiluminescent assay (CLIA) and the Single Molecular Array (Simoa) assay. Viremia thresholds for severity were determined and proposed. In severe patients, the peak antigen response was observed 7 days after the onset of symptoms, followed by a decline. No real peak response was observed in non-severe patients. Severity thresholds for the Simoa and the CLIA provided positive likelihood ratios of 30.0 and 10.9 for the timeframe between day 2 and day 14, respectively. Sensitive detection of N antigens in serum may thus provide a valuable new marker for COVID-19 diagnosis and evaluation of disease severity. When assessed during the first 2 weeks since the onset of symptoms, it may help in identifying patients at risk of developing severe COVID-19 to optimize better intensive care utilization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Viruses - 14(2022), 8 vom: 28. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Favresse, Julien [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigenic assay |
|---|
| Anmerkungen: |
Date Completed 29.08.2022 Date Revised 02.09.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v14081653 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34534670X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34534670X | ||
| 003 | DE-627 | ||
| 005 | 20231226024847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v14081653 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM34534670X | ||
| 035 | |a (NLM)36016276 | ||
| 035 | |a (PII)1653 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Favresse, Julien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2022 | ||
| 500 | |a Date Revised 02.09.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The diagnostic of SARS-CoV-2 infection relies on reverse transcriptase polymerase chain reactions (RT-PCRs) performed on nasopharyngeal (NP) swabs. Nevertheless, false-negative results can be obtained with inadequate sampling procedures, making the use of other biological matrices worthy of investigation. This study aims to evaluate the kinetics of serum N antigens in severe and non-severe patients and compare the clinical performance of serum antigenic assays with NP RT-PCR. Ninety patients were included in the study and monitored for several days. Disease severity was determined according to the WHO clinical progression scale. Serum N antigen levels were measured with a chemiluminescent assay (CLIA) and the Single Molecular Array (Simoa) assay. Viremia thresholds for severity were determined and proposed. In severe patients, the peak antigen response was observed 7 days after the onset of symptoms, followed by a decline. No real peak response was observed in non-severe patients. Severity thresholds for the Simoa and the CLIA provided positive likelihood ratios of 30.0 and 10.9 for the timeframe between day 2 and day 14, respectively. Sensitive detection of N antigens in serum may thus provide a valuable new marker for COVID-19 diagnosis and evaluation of disease severity. When assessed during the first 2 weeks since the onset of symptoms, it may help in identifying patients at risk of developing severe COVID-19 to optimize better intensive care utilization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a RT-PCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antigenic assay | |
| 650 | 4 | |a prognosis test | |
| 700 | 1 | |a Bayart, Jean-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a David, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Gillot, Constant |e verfasserin |4 aut | |
| 700 | 1 | |a Wieërs, Grégoire |e verfasserin |4 aut | |
| 700 | 1 | |a Roussel, Gatien |e verfasserin |4 aut | |
| 700 | 1 | |a Sondag, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Elsen, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Eucher, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 14(2022), 8 vom: 28. Juli |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:8 |g day:28 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v14081653 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 8 |b 28 |c 07 | ||